USA Antidiabetic SGLT-2 Inhibitor Market Report 2018

Table of Contents

1 Report Overview

• 1.1 Definition and Specification
• 1.2 Report Overview
  • 1.2.1 Manufacturers Overview
  • 1.2.2 Regions Overview
  • 1.2.3 Type Overview
  • 1.2.4 Application Overview
• 1.3 Industrial Chain
  • 1.3.1 Antidiabetic SGLT-2 Inhibitor Overall Industrial Chain
  • 1.3.2 Upstream
  • 1.3.3 Downstream
• 1.4 Industry Situation
  • 1.4.1 Industrial Policy
  • 1.4.2 Product Preference
  • 1.4.3 Economic/Political Environment
• 1.5 SWOT Analysis

2 Market Analysis by Types

• 2.1 Overall Market Performance(Volume)
  • 2.1.1 Canagliflozin Market Performance (Volume)
  • 2.1.2 Empagliflozin Market Performance (Volume)
  • 2.1.3 Dapagliflozin Market Performance (Volume)
  • 2.1.4 Other Market Performance (Volume)
• 2.2 Overall Market Performance(Value)
  • 2.1.1 Canagliflozin Market Performance (Value)
  • 2.1.2 Empagliflozin Market Performance (Value)
  • 2.1.3 Dapagliflozin Market Performance (Value)
  • 2.1.4 Other Market Performance (Value)

3 Product Application Market

• 3.1 Overall Market Performance (Volume)
  • 3.1.1 Hospitals Market Performance (Volume)
  • 3.1.2 Clinics Market Performance (Volume)
  • 3.1.3 Other Market Performance (Volume)

4 Manufacturers Profiles/Analysis

• 4.1 Pfizer
  • 4.1.1 Pfizer Profiles
  • 4.1.2 Pfizer Product Information
  • 4.1.3 Pfizer Antidiabetic SGLT-2 Inhibitor Business Performance
  • 4.1.4 Pfizer Antidiabetic SGLT-2 Inhibitor Business Development and Market Status
• 4.2 AstraZeneca
  • 4.2.1 AstraZeneca Profiles
  • 4.2.2 AstraZeneca Product Information
  • 4.2.3 AstraZeneca Antidiabetic SGLT-2 Inhibitor Business Performance
  • 4.2.4 AstraZeneca Antidiabetic SGLT-2 Inhibitor Business Development and Market Status
• 4.3 Johnson & Johnson
  • 4.3.1 Johnson & Johnson Profiles
  • 4.3.2 Johnson & Johnson Product Information
  • 4.3.3 Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Business Performance
  • 4.3.4 Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Business Development and Market Status
• 4.4 GlaxoSmithKline
  • 4.4.1 GlaxoSmithKline Profiles
  • 4.4.2 GlaxoSmithKline Product Information
  • 4.4.3 GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Business Performance
  • 4.4.4 GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Business Development and Market Status
• 4.5 Merck & Co
  • 4.5.1 Merck & Co Profiles
  • 4.5.2 Merck & Co Product Information
  • 4.5.3 Merck & Co Antidiabetic SGLT-2 Inhibitor Business Performance
  • 4.5.4 Merck & Co Antidiabetic SGLT-2 Inhibitor Business Development and Market Status
• 4.6 Eli Lilly
  • 4.6.1 Eli Lilly Profiles
  • 4.6.2 Eli Lilly Product Information
  • 4.6.3 Eli Lilly Antidiabetic SGLT-2 Inhibitor Business Performance
  • 4.6.4 Eli Lilly Antidiabetic SGLT-2 Inhibitor Business Development and Market Status
• 4.7 Sanofi
  • 4.7.1 Sanofi Profiles
  • 4.7.2 Sanofi Product Information
  • 4.7.3 Sanofi Antidiabetic SGLT-2 Inhibitor Business Performance
  • 4.7.4 Sanofi Antidiabetic SGLT-2 Inhibitor Business Development and Market Status
• 4.8 Takeda Pharmaceuticals
  • 4.8.1 Takeda Pharmaceuticals Profiles
  • 4.8.2 Takeda Pharmaceuticals Product Information
  • 4.8.3 Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Business Performance
  • 4.8.4 Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Business Development and Market Status
• 4.9 Novo Nordisk
  • 4.9.1 Novo Nordisk Profiles
  • 4.9.2 Novo Nordisk Product Information
  • 4.9.3 Novo Nordisk Antidiabetic SGLT-2 Inhibitor Business Performance
  • 4.9.4 Novo Nordisk Antidiabetic SGLT-2 Inhibitor Business Development and Market Status
• 4.10 Servier Laboratories
  • 4.10.1 Servier Laboratories Profiles
  • 4.10.2 Servier Laboratories Product Information
  • 4.10.3 Servier Laboratories Antidiabetic SGLT-2 Inhibitor Business Performance
  • 4.10.4 Servier Laboratories Antidiabetic SGLT-2 Inhibitor Business Development and Market Status
• 4.11 Boehringer Ingelheim
• 4.12 Bristol-Myers Squibb

5 Market Performance for Manufacturers

• 5.1 USA Antidiabetic SGLT-2 Inhibitor Sales (K Units) and Market Share by Manufacturers 2013-2018
• 5.2 USA Antidiabetic SGLT-2 Inhibitor Revenue (M USD) and Market Share by Manufacturers 2013-2018
• 5.3 USA Antidiabetic SGLT-2 Inhibitor Price (USD/Unit) of Manufacturers 2013-2018
• 5.4 USA Antidiabetic SGLT-2 Inhibitor Gross Margin of Manufacturers 2013-2018
• 5.5 Market Concentration

6 Regions Market Performance for Manufacturers

• 6.1 Northeast Market Performance for Manufacturers
  • 6.1.1 Northeast Antidiabetic SGLT-2 Inhibitor Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.1.2 Northeast Antidiabetic SGLT-2 Inhibitor Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.1.3 Northeast Antidiabetic SGLT-2 Inhibitor Price (USD/Unit) of Manufacturers 2013-2018
  • 6.1.4 Northeast Antidiabetic SGLT-2 Inhibitor Gross Margin of Manufacturers 2013-2018
  • 6.1.5 Market Concentration
• 6.2 Midwest Market Performance for Manufacturers
  • 6.2.1 Midwest Antidiabetic SGLT-2 Inhibitor Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.2.2 Midwest Antidiabetic SGLT-2 Inhibitor Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.2.3 Midwest Antidiabetic SGLT-2 Inhibitor Price (USD/Unit) of Manufacturers 2013-2018
  • 6.2.4 Midwest Antidiabetic SGLT-2 Inhibitor Gross Margin of Manufacturers 2013-2018
  • 6.2.5 Market Concentration
• 6.3 South Market Performance for Manufacturers
  • 6.3.1 South Antidiabetic SGLT-2 Inhibitor Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.3.2 South Antidiabetic SGLT-2 Inhibitor Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.3.3 South Antidiabetic SGLT-2 Inhibitor Price (USD/Unit) of Manufacturers 2013-2018
  • 6.3.4 South Antidiabetic SGLT-2 Inhibitor Gross Margin of Manufacturers 2013-2018
  • 6.3.5 Market Concentration
• 6.4 West Market Performance for Manufacturers
  • 6.4.1 West Antidiabetic SGLT-2 Inhibitor Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.4.2 West Antidiabetic SGLT-2 Inhibitor Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.4.3 West Antidiabetic SGLT-2 Inhibitor Price (USD/Unit) of Manufacturers 2013-2018
  • 6.4.4 West Antidiabetic SGLT-2 Inhibitor Gross Margin of Manufacturers 2013-2018
  • 6.4.5 Market Concentration

7 USA Antidiabetic SGLT-2 Inhibitor Market Performance (Sales Point)

• 7.1 USA Antidiabetic SGLT-2 Inhibitor Sales (K Units) and Market Share by Regions 2013-2018
• 7.2 USA Antidiabetic SGLT-2 Inhibitor Revenue (M USD) and Market Share by Regions 2013-2018
• 7.3 USA Antidiabetic SGLT-2 Inhibitor Price (USD/Unit) by Regions 2013-2018
• 7.4 USA Antidiabetic SGLT-2 Inhibitor Gross Margin by Regions 2013-2018

8 Development Trend for Regions (Sales Point)

• 8.1 USA Antidiabetic SGLT-2 Inhibitor Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.2 Northeast Antidiabetic SGLT-2 Inhibitor Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.3 Midwest Antidiabetic SGLT-2 Inhibitor Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.4 South Antidiabetic SGLT-2 Inhibitor Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.5 West Antidiabetic SGLT-2 Inhibitor Sales and Growth, Sales Value and Growth Rate2013-2018

9 Upstream Source, Technology and Cost

• 9.1 Upstream Source
• 9.2 Technology
• 9.3 Cost

10 Channel Analysis

• 10.1 Market Channel
• 10.2 Distributors

11 Consumer Analysis

• 11.1 Hospitals Industry
• 11.2 Clinics Industry
• 11.3 Other Industry

12 Market Forecast 2019-2024

• 12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2019-2024
  • 12.1.1 USA Antidiabetic SGLT-2 Inhibitor Sales (K Units), Revenue (M USD) and Market Share by Regions 2019-2024
  • 12.1.2 USA Antidiabetic SGLT-2 Inhibitor Sales (K Units) and Growth Rate 2019-2024
  • 12.1.3 Northeast Antidiabetic SGLT-2 Inhibitor Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.4 Midwest Antidiabetic SGLT-2 Inhibitor Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.5 South Antidiabetic SGLT-2 Inhibitor Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.6 West Antidiabetic SGLT-2 Inhibitor Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.7 Antidiabetic SGLT-2 Inhibitor Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.8 Antidiabetic SGLT-2 Inhibitor Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.9 Antidiabetic SGLT-2 Inhibitor Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.10 Antidiabetic SGLT-2 Inhibitor Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
• 12.3 Sales (K Units), Revenue (M USD) by Types 2019-2024
  • 12.3.1 Overall Market Performance
  • 12.3.2 Canagliflozin Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.3.3 Empagliflozin Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.3.4 Dapagliflozin Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.3.5 Other Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
• 12.4 Sales by Application 2019-2024
  • 12.4.1 Overall Market Performance
  • 12.4.2 Hospitals Sales and and Growth Rate 2019-2024
  • 12.4.3 Clinics Sales and and Growth Rate 2019-2024
  • 12.4.4 Other Sales and and Growth Rate 2019-2024
• 12.5 Price (USD/Unit) and Gross Profit
  • 12.5.1 USA Antidiabetic SGLT-2 Inhibitor Price (USD/Unit) Trend 2019-2024
  • 12.5.2 USA Antidiabetic SGLT-2 Inhibitor Gross Profit Trend 2019-2024

13 Conclusion